Daily Dose - Sep 2nd, 2026
Daily Dose |
View online
September 2, 2026
ARPA-H’s $125M effort to make individualized, RNA-based genetic medicines on demand
Five teams will create automated platforms capable of producing RNA-based genetic medicines and performing quality control testing at or near the point of care.
Read More
Andelyn Biosciences to scale manufacturing for Genprex diabetes gene therapy
The collaboration will support process optimization, scale-up, and cGMP manufacturing for Genprex’s AAV-based diabetes gene therapy candidate.
Read More
Devonian validates quality control methods for botanical drug manufacturing
The company has validated chemical fingerprinting and biological potency assays to assess batch-to-batch consistency of its botanical drug candidate.
Read More
